Norway· NO-ID_876BB9B8-14F8-4461-B7AB-EC118932CBDC
Pemazyre
A pemigatinib product containing pemigatinib, registered in Norway by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Pemigatinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN02 (pemigatinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Pemigatinib · ATC L01EN02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pemigatinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pemigatinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1227.26
The record
At a glance
FEST (Norway)- Active substance
- Pemigatinib
- Manufacturer
- Incyte Biosciences Distribution B.V.
- Country
- Norway (NO)
- ATC code
- L01EN02
- ATC class
- Pemigatinib
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_876BB9B8-14F8-4461-B7AB-EC118932CBDC
- no_varenummer53315714NOK 103000.3
- gtin7640159432647
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
71 interactions on record for pemigatinib.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pemigatinib · interactions on record
71 records
- 30 severe
- 41 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pemigatinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPEMAZYREIncyte Biosciences Distribution B.V., Amsterdam
- SwitzerlandPemazyre 4,5 mg, comprimésIncyte Biosciences International Sàrl
- United StatesPEMAZYREIncyte Corporation
- FrancePEMAZYRE 4,5 mg, compriméINCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- CanadaPEMAZYREINCYTE CORPORATION
- IrelandPemazyre 4.5 mg tabletsIncyte Biosciences Distribution B.V.
- IcelandPemazyreIncyte Biosciences Distribution B.V.
- NetherlandsPemazyre 4,5 mg, tablettenIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Pemazyre
- Liechtenstein · Pemazyre
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9db972ce-df13-4bfc-9168-8c61e5411fa8 GET /v1/drugs/9db972ce-df13-4bfc-9168-8c61e5411fa8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett",
"source": "fest",
"status": "A",
"atc_name": "Pemigatinib",
"merkevare_id": "ID_876BB9B8-14F8-4461-B7AB-EC118932CBDC",
"name_form_strength": "Pemazyre tab 4,5 mg",
"prescription_group": "C"
}See everything about pemigatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.